José Baselga, MD, PhD
José Baselga, MD, is EVP of Research & Development Oncology at AstraZeneca and professor of medicine at Weill Cornell Medical College. Prior to joining AstraZeneca, José was the physician-in-chief at Memorial Sloan Kettering Cancer Center and held several executive-level roles in medicine at Harvard Medical School and Massachusetts General Hospital.
He is also involved in many industry-leading groups, as past president of the American Association of Cancer Research (AACR), past president of the European Society for Medical Oncology, and a past member of the board of directors for the American Society of Clinical Oncology. He also served as founding director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. Currently, José is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, and the Association of American Physicians, and a fellow of the AACR Academy. He is the founding editor-in-chief of Cancer Discovery, AACR’s flagship journal, and is a past editorial board member for Cancer Cell, Journal of Clinical Oncology, and Clinical Cancer Research.
A prolific researcher with more than 470 peer-reviewed publications to date, José has longstanding research interests in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance. He conducted pivotal laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab, and everolimus, among other therapies. His current work is in targeting PI3K and deciphering mechanisms of resistance to anti-estrogen therapies.
He holds both an MD and PhD from the Autonomous University of Barcelona.